



61  
AF/1644  
Attorney Docket No. 018733/0967

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David M. GOLDENBERG *et al.*

Title: IMMUNOTHERAPY OF  
AUTOIMMUNE DISORDERS  
USING ANTIBODIES WHICH  
TARGET B-CELLS

Appl. No.: 09/590,284

Filing Date: June 9, 2000

Examiner: J. Roark

Art Unit: 1644

RECEIVED

JUL 08 2003

TECH CENTER 1600/2900

REQUEST FOR RECONSIDERATION UNDER 37 CFR §1.116

Commissioner for Patents  
Washington, D.C. 20231

Sir:

OK to enter  
9/15/03 JMR  
In reply to the communication dated April 4, 2003, applicants request that the above-identified application be reconsidered in light of the remarks that follow.

Claims 1-5, 7, 12-15, 37 and 38 are pending. Claims 6, 8-11, and 16-36 are withdrawn from consideration as directed to a non-elected species. Upon allowance of a generic claim, these claims should be examined in the present case. Claims 1-5, 7, 12-15, 37 and 38 are rejected. Claims 1-5, 7, 12-15, 37 and 38 remain in the case.

Claim 5 is rejected under the first paragraph of Section 112. According to the examiner, the LL2 antibody must be known and readily available to the public or obtainable by a repeatable method set forth in the specification. Forwarded with this response are papers evidencing a deposit of the LL2 antibody that has been made in another of the assignee's cases, which inadvertently was missing from applicant's previous submission. Withdrawal of the rejection of claim 5 is respectfully requested.